Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jeffrey Borer"'
Autor:
Michael Böhm, Michele Robertson, Jeffrey Borer, Ian Ford, Michel Komajda, Felix Mahfoud, Sebastian Ewen, Karl Swedberg, Luigi Tavazzi
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 2 (2016)
BackgroundElevated resting heart rate (HR) and low systolic blood pressure (SBP) are related to poor outcomes in heart failure (HF). The association between visit‐to‐visit variation in SBP and HR and risk in HF is unknown. Methods and ResultsIn S
Externí odkaz:
https://doaj.org/article/94b8762d00a14cbd8f705e6088c98f7b
Recognize when lower extremity disorders signal a larger problem. Systemic Disease Manifestations in the Foot, Ankle, and Lower Extremity is the first clinical reference focused on helping you recognize when lower extremity symptoms indicate the pres
Autor:
Michael Böhm, Amr Abdin, Jonathan Slawik, Felix Mahfoud, Jeffrey Borer, Ian Ford, Karl Swedberg, Luigi Tavazzi, Cécile Batailler, Michel Komajda
Publikováno v:
European Journal of Heart Failure.
Autor:
Aleksandra, Nikolovska Vukadinović, Davor, Vukadinović, Jeffrey, Borer, Martin, Cowie, Michel, Komajda, Mitja, Lainscak, Karl, Swedberg, Michael, Böhm
Publikováno v:
European journal of heart failure. 19(10)
Heart rate (HR) is associated with cardiovascular outcomes in all the stages of the cardiovascular continuum as well as in patients with pulmonary, cerebrovascular, and renal disease, sepsis, cancer, and erectile dysfunction. In patients with cardiov
Autor:
Kimberly Brown, Jonathan Hansen, Thomas F. Luscher, Danielle M. Brennan, Jeffrey Borer, Venu Menon, A M Lincoff, Steven E. Nissen
Publikováno v:
Journal of the American College of Cardiology. 71:A415
Left ventricular hypertrophy (LVH) is an independent risk factor for cardiovascular (CV) mortality. The PRECISION trial evaluated the CV safety of celecoxib and nonselective NSAIDs. We assessed the contemporary impact of LVH on CV outcomes diagnosed
Autor:
Mingyuan Shao, A M Lincoff, Kathy Wolski, Grant W. Reed, Mouin Abdallah, Neville Yeomans, Peter Libby, Thomas F. Luscher, Steven E. Nissen, Lisa Wisniewski, Elaine Husni, David Y. Graham, Jeffrey Borer, Venuy Menon, Daniel H. Solomon
Publikováno v:
Journal of the American College of Cardiology. 71:A85
The PRECISION trial demonstrated the non-inferiority of celecoxib to ibuprofen or naproxen for cardiovascular (CV) safety in patients with arthritis. A comparison of the overall safety of each agent stratified by drug dose has yet to be reported. Pat
Autor:
Mitchell Dul, Sharon Nachman, Vanessa Arnedo, Clotilde Balucani, Dee Burton, Abhishek Pandey, Ziad El Zammar, Jeffrey Borer, Phyllis Supino, Steven R Levine
Publikováno v:
Stroke. 44
Background: Innovative strategies are needed to improve blood pressure (BP) surveillance and treatment given the generally poor control in minority communities. People may be more likely to have yearly eye exams than have an annual physical. Objectiv
Autor:
Karl, Swedberg, Michel, Komajda, Michael, Böhm, Jeffrey, Borer, Michele, Robertson, Luigi, Tavazzi, Ian, Ford
Publikováno v:
Journal of the American College of Cardiology. 59(22)
This study used the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) database to assess the impact of background beta-blocker dose on response to ivabradine.In systolic heart failure, reduction in relatively high hear
Autor:
Michael, Domanski, Stuart, Pocock, Corine, Bernaud, Jeffrey, Borer, Nancy, Geller, James, Revkin, Faiez, Zannad
Publikováno v:
Fundamentalclinical pharmacology. 25(4)
Surrogate endpoints predict the occurrence and timing of a clinical endpoint of interest (CEI). Substitution of a surrogate endpoint for a CEI can dramatically reduce the time and cost necessary to complete a Phase III clinical trial. However, assura
Autor:
James E. Dalen, Joel M. Gore, Eugene Braunwald, Jeffrey Borer, Robert J. Goldberg, Eugene R. Passamani, Sandra Forman, Genell Knatterud, null The TIMI Investigators
Publikováno v:
The American journal of cardiology. 62(4)
The Thrombolysis in Myocardial Infarction (TIMI) trial Phase I was designed to compare the efficacy and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) and intravenous streptokinase (SK) in patients with acute myocar